Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Average (2021 - 2025)

Historic Equity Average for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $515.2 million.

  • Kiniksa Pharmaceuticals International's Equity Average rose 1815.03% to $515.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $515.2 million, marking a year-over-year increase of 1815.03%. This contributed to the annual value of $438.6 million for FY2024, which is 506.44% up from last year.
  • Kiniksa Pharmaceuticals International's Equity Average amounted to $515.2 million in Q3 2025, which was up 1815.03% from $476.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Equity Average's 5-year high stood at $515.2 million during Q3 2025, with a 5-year trough of $159.9 million in Q2 2022.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Equity Average value was $404.6 million (recorded in 2023), while the average stood at $359.9 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Equity Average plummeted by 3687.07% in 2022 and then soared by 15075.25% in 2023.
  • Kiniksa Pharmaceuticals International's Equity Average (Quarter) stood at $199.5 million in 2021, then skyrocketed by 95.49% to $390.1 million in 2022, then increased by 8.18% to $422.0 million in 2023, then grew by 3.73% to $437.7 million in 2024, then rose by 17.7% to $515.2 million in 2025.
  • Its Equity Average was $515.2 million in Q3 2025, compared to $476.2 million in Q2 2025 and $448.0 million in Q1 2025.